Induction of weight loss and metabolic alterations by human recombinant tumour necrosis factor. by Mahony, S. M. & Tisdale, M. J.
Br. J. Cancer (1988), 58, 345-349
Induction of weight loss and metabolic alterations by human
recombinant tumour necrosis factor
S.M. Mahony & M.J. Tisdale
CRC Experimental Chemotherapy Group, Pharmaceutical Sciences Institute, Aston University, Birmingham B4 7ET, UK.
Summary A comparison has been made of the weight loss produced by tumour necrosis factor (TNF)
(cachectin) with that produced by a restricted food and water intake (pair-fed controls), and by mitozolomide,
a drug which in toxic doses induces weight loss with a similar decrease in nutrient and water intake. When
administered as two separate injections over a 24h period (acute administration) TNF produced a dose-
related weight reduction that was accompanied by and directly proportional to a decrease in both food and
water intake. When administered daily by i.v. injection over a 5-day period (chronic administration) the major
weight loss was found to occur during the first 24h after injection and thereafter the weight of treated mice
increased toward that of controls. Acute administration of TNF produced hypoglycaemia that was more
severe than observed with either mitozolomide or in pair-fed controls, a reduction in the circulatory level of
free fatty acids (FFA) and an increase in plasma triglycerides, while mitozolomide and pair-feeding had no
effect on the level of blood glucose or plasma triglycerides. Body composition analysis showed a loss of
adipose tissue in TNF-injected and pair-fed animals after both acute and chronic treatment. Acute
administration of TNF also induced a decrease in the total body water content of treated aniimals which was
similar to pair-fed controls. It is concluded that the weight loss produced by TNF arises from a combination
of semi-starvation and a reduced water intake, and that the effect only occurred with the first administration
of TNF.
Cachexia is often reported as the most frequent cause of
death in cancer patients (Robbins, 1962) and is characterized
by the development of progressive weakness, weight loss and
wasting. The frequency of cancer cachexia varies with
tumour type, with gastrointestinal cancers and lung cancer
having the greatest incidence (Strain, 1979). Cachexia may
occur with a small primary tumour and may precede the
clinical diagnosis. The weight loss associated with cachexia
may be accompanied by marked anorexia (Garrattini et al.,
1980). However, cancer cachexia is more like the condition
produced by a major injury or sepsis, rather than that due to
simple starvation (Brennan, 1977). Anorexia seems to be
only a partial cause of the wasting process, since in both rat
and man loss of both muscle and adipose tissue frequently
precedes a fall in food intake (Costa, 1963). This suggests
that metabolic disturbances within the tumour or the host
tissues also contribute.
Several tumour-associated factors with a possible signifi-
cance in the aetiology of the cachectic syndrome have been
reported. Most recently a macrophage product, cachectin,
has been suggested to orchestrate the complex metabolic
changes that lead to cachexia. Cachectin has been shown to
inhibit lipoprotein lipase activity in adipose tissue resulting
in a marked elevation of plasma very low density lipoprotein
(Beutler et al., 1985a). Cachectin is an acidic protein which
has been shown to be homologous to tumour necrosis factor
(TNF) (Beutler et al., 1985b), a macrophage product of
molecular weight 17,000 that can be induced by endotoxin
and other microbial products. When mice were passively
immunized with a highly specific polyclonal rabbit antiserum
directed against murine TNF they were protected against the
lethal effect of the endotoxin lypopolysaccharide produced
by E. coli (Beutler et al., 1985c). This suggests that
cachectin/TNF is one of the principal mediators of the lethal
effect of endotoxin. In addition a considerable amount of
evidence has implicated cachectin as a central mediator of
the wasting that accompanies chronic invasive disease states
(Beutler & Cerami, 1986). Animals inoculated intramuscu-
larly with a rodent tumour cell line which continuously
secretes human TNF were recently shown to develop severe
cachexia and weight loss (Oliff et al., 1987).
In order to evaluate the role of TNF in cachexia we have
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compared the parameters contributing to weight loss pro-
duced by human recombinant TNF with that in pair-fed
animals and in animals injected with mitozolomide, a drug
which in toxic doses also induces weight loss with a decrease
in nutrient and water intake. The effects of acute and of
chronic administration of TNF on NMRI mice are
compared.
Materials and methods
Animals
Pure strain NMRI mice (age 6-8 weeks) were purchased
from Banting and Kingman, Hull, UK, and were fed ad lib.
a rat and mouse breeding diet (Pilsbury's, Birmingham, West
Midlands, UK). All animals were given free access to food
and water and both food and water intake were monitored
daily.
TNF
Human recombinant TNF (6 x 10 Umg1) was kindly
donated by Boehringer Ingelheim Ltd., Bracknell, Berks and
stored at 4°C. The endotoxin content was <0.125EUml-1.
Fresh solutions of TNF were made up daily in 0.9% NaCl
and 200pI of the appropriate concentration of TNF was
injected into the tail veins of female NMRI mice (19-22g).
Controls were injected with 200pl 0.9% NaCl. Injections
were administered at the same time each day for 5 days
(chronic dosage) or as two separate injections over a 24h
period (acute dosage). Body weights and food and water
intake were monitored daily. Food intake was measured by
weighing the pellets remaining. Food wastage was minimal
using pelleted food. Water consumption was determined by
volume. Water bottles contained a ball valve to prevent
dripping. Blood was removed by cardiac puncture from
animals under anaesthesia I h after the final injection of
TNF.
Mitozolomide
Fresh solutions of mitozolomide (May and Baker Ltd.,
Dagenham, UK) in arachis oil containing 10% DMSO were
made up daily and 20mgkg-1 were injected i.p. into female
NMRI mice (19.3+0.15g). Controls were injected with
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Table I Effect of recombinant TNF, mitozolomide and pair-feeding on body weight, blood glucose and
the plasma level of triglycerides*
Weight changea Glucose Triglyceride
Treatment (g) (mg JOOml-1) (mM)
Controls - no treatment +0.08+0.3 122+ 5 1.23 +0.2
Controls i.v. saline -0.19+0.1 120+ 4 1.01 +0.2
Controls - i.p. arachis oil + 10% DMSO -0.46+0.2 117+ 5 1.32+0.2
Controls - pair-fed -2.34+0.3_b 128+
I lb 1.49+0.4
Mitozolomide - 20mgkg 1 1.22+0.2c 105+ 7 1.47+0.1
TNF 1.5x 107Ukg- -0.73+0.5 89+ 3d 2.71+0.2d
TNF 3.0x107Ukg-1 -1.38+0.4d 71+ 8d 2.52+O.Id
TNF 4.5 x 107 Ukg-1 -1.62+0.3d 58+ 3d 2.43+0.4d
TNF 6.0 x 107 Ukg-1 -1.60+0.4d 56+ gd 2.34+O Id
TNF 7.5 x 107 Ukg- -2.08 +0.4d 44+ 4d 2.37+0.2d
*Results are given as means+s.e.m. for 6 to 13 animals per group; aThe weight change over 24h for
TNF-treated, pair-fed and mitozolomide-treated mice; bp<0.001 from controls (no treatment); CP<0.001
from arachis oil +10% DMSO infused controls; dp<0.001 from saline infused on pair-fed controls.
arachis oil containing 10% DMSO. Body weights and food
and water intake were monitored and blood was removed by
cardiac puncture from animals under anaesthesia 24h after
the injection.
Pair-feeding
Female NMRI mice (19.2+0.46g) were given the same
amount of food and water (given every 6h) both over a 24h
period (acute) and over a 5 day period (chronic) as that
consumed by mice following injection of 7.5 x 107 Ukg-
TNF. Body weights were then monitored and blood was
removed by cardiac puncture from animals under
anaesthesia.
Metabolite determinations
Blood glucose was determined on whole blood with the use
of the o-toluidine reagent kit (Sigma Chemical Co., Dorset,
UK). FFA levels were measured in plasma with a WAKO
NEFA C kit (Alpha Laboratories, Hampshire, UK). Plasma
triglycerides were determined with a triglyceride diagnostic
kit (Sigma Diagnostics, Dorset, UK).
Body composition analysis
The gastrocnemius and thigh muscles from the left hind leg
of mouse carcasses were carefully dissected out and weighed,
together with the whole carcass. Each carcass plus muscles
were heated at 80°C until a constant weight was achieved.
Carcasses were then reweighed and the water content was
determined from the difference between the wet and dry
weights. Total carcass fat was determined by the method of
Lundholm et al. (1980).
Statistical analysis
All results were analysed statistically using the analysis of
variance or F-ratio.
Results
Human recombinant TNF administered i.v. causes a dose-
related weight loss after two separate injections over a 24h
period (Table I), which is significantly greater than the saline
injected controls at all concentrations of TNF employed.
Mice receiving daily injections of TNF exhibit a biphasic
decrease in the relative body mass, which is dose-related
(Figure 1). No morbidity or mortality was observed with any
of 'the concentrations of TNF employed. When the actual
daisy weight loss for the three concentrations of TNF are
plotted (Figure 2), it can be seen that all of the weight loss
occurs during the first 24h after injection and thereafter the
body weight increases towards that of saline injected
controls, despite further daily injections of TNF.
Both the food and water consumption of mice receiving
daily injections of TNF closely follows the pattern of weight
loss (Figures 3 and 4) with an initial dose-dependent sharp
decrease, followed after a period of I to 2 days in an
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Figure 1 Effect of daily administration of TNF on the weight of
female NMRI mice expressed as percentage relative body mass.
Human recombinant TNF was administered daily by i.v. injec-
tion over a 5 day period and the animals were killed 1 h after the
final injection. The average of the body mass of the animals in
each group at day 0 was taken as 100%. Animals were infused
with saline (L) or with 4.5xlO7Ukg-1 (*), 6.Ox1O7Ukg-1
(l) or 7.5 x 107 Ukg - (O) of TNF. (a) P<0.001 from control
by analysis of variance.
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Figure 2 Effect of daily administration of TNF on the weight
female NMRI mice. Animals were infused with saline (LI)
or with 4.5x107Ukg-l (*), 6.OxlO7Ukg- 1 () or
7.5 x l07 Ukg-1 (O) of TNF. The values represent means+s.e.m.
for 6 to 13 animals for each concentration of TNF. Error bars
were omitted in order to simplify the diagram. (a) P<0.01, (b)
P<0.005, (c) P<0.001 from control by analysis of variance.WEIGHT LOSS INDUCED BY TNF 347
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Figure 3 Effect of daily administration of TNF on the food
consumption of female NMRI mice as measured at the same
time each day. The values represent the means+s.e.m. for 4 to 13
animals for each concentration of TNF. Error bars were omitted
in order to simplify the diagram.. The symbols represent the
same concentration of TNF as in Figures 1 and 2. (a) P<0.005
from control by analysis of variance.
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Figure 5 Variation of weight loss (g) during a 24h period after
administration of TNF with the difference in food (Kcal
mouse-') and water (ml) consumption between a saline infused
group and TNF treated groups. The results were fitted to a
linear model by means of a least squares analysis (r= -0.92).
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Figure 4 Effect of daily administration of TNF on the water
consumption of female NMRI mice as measured at the same
time each day. The values represent the means+s.e.m. for 4 to 13
animals for each concentration of TNF. Error bars were omitted
in order to simplify the diagram. The symbols represent the same
concentrations of TNF as in Figures I and 2. (a) P<0.005 from
control by analysis of variance.
increased consumption towards the levels found in the
controls. The initial decrease in food and water intake is
directly proportional to the decrease in body weight of the
animals over the first 24h (Figure 5). Animals given the
same amount of food and water as that consumed by those
injected with the highest concentration of TNF
(7.5 x 107Ukg-1) lost the same amount of weight over a
24h period (Table I). Mitozolomide is a cytotoxic drug,
which at a concentration of 20mgkg-1 causes general
malaise and a decrease in food and water consumption equal
to that obtained with 7.5 x 107 Ukg - of TNF. The results
in Table I show that there is no significant difference
between the weight loss produced by mitozolomide and the
equivalent concentration of TNF, suggesting that weight loss
produced by TNF may be due to a generalized cytotoxicity.
TNF treated mice show a highly significant hypoglycaemia
60 to 90min after the second of 2 injections over a 24h
period, but not after 5 daily injections of TNF (Figure 6,
Table I). The TNF-induced hypoglycaemia is directly pro-
portional to both the decrease in body weight (Figure 7) and
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Figure 6 Comparison of the effects of acute and chronic ad-
ministration of TNF on the blood glucose concentration of
female NMRI mice. The values represent the means+s.e.m. for 4
to II (acute dosage) (U) or 6 to 13 (chronic dosage) (E]) animals
for each concentration of TNF. (a) P<0.001 from saline infused
controls by analysis of variance.
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Figure 7 Variation of blood glucose concentration (mg
100ml-1) with weight loss (g) during a 24h period after
administration of TNF. The results were fitted to a linear model
by means of a least square analysis (r= -0.99).
to the decrease in food and water consumption over the first
24h following injection (Figure 8), and is much more
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Figure 8 Variation of blood glucose concentration (mg
100ml-') with the difference of food (Kcal mouse-') and water
(ml) consumption during a 24h period between a saline infused
group and the TNF treated groups. The results were fitted to a
linear model by means of a least squares analysis (r=0.98).
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Figure 10 Comparison of the effects of acute (0) and chronic
(n) administration of TNF on the plasma NEFA concentration
of female NMRI mice. The values represent the means+s.e.m.
for 4 to 7 (acute dosage) or 6 to 13 (chronic dosage) animals for
each concentration of TNF. (a) P<0.005, (b) P<0.001 from
saline infused controls by analysis of variance.
pronounced than observed in weight-losing, pair-fed or
mitozolomide-treated animals (Table I).
Marked hypertriglyceridemia is observed after acute ad-
ministration of TNF (Figure 9, Table I) and may be either
due to inhibition of lipoprotein lipase activity, or to
increased hepatic triglyceride synthesis (Feingold et al.,
1987). This increase in triglyceride levels is also directly
proportional to the decrease in food and water consumption
of treated animals as compared to control (r= -0.93). In
contrast, pair-feeding and mitozolomide induced no signifi-
cant changes in plasma triglyceride levels of treated animals.
Plasma levels of FFA were reduced after acute TNF adminis-
tration, but not after chronic administration (Figure 10).
The decrease in body weight was accompanied by a dose-
related decrease in total body fat after both acute and
chronic administration of TNF when compared with saline
infused controls (Table II). There was no difference in body
fat content between the TNF treated and pair-fed controls.
There was a decrease in total body water content after acute
administration, but an increase was observed after 5 daily
injections of TNF, when compared with saline infused
controls. There was no difference in body water between
TNF treated, pair-fed or mitozolomide treated animals. No
change in thigh and gastrocnemius muscle content was
observed after either acute or chronic administration of
TNF. No change was observed in the body composition of
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Figure 9 Comparison of the effects of acute (0) and chronic
( ) administration of TNF on the plasma triglyceride con-
centration of female NMRI mice. The values represent the
means+s.e.m. for 4 to 11 (acute dosage) or 6 to 13 (chronic
dosage) animals for each concentration of TNF. (a) P<0.05, (b)
P<0.001 from saline infused controls by analysis of variance.
mitozolomide-treated mice as compared to arachis oil
injected controls except for a decrease in carcass water
content.
Discussion
Daily administration of TNF to female NMRI mice has
been shown to induce a transient state of anorexia with the
ensuing weight loss being directly proportional to the
decrease in food and water intake. A similar effect has been
observed by Cerami et al. (1985) in mice injected with
dialysed conditioned medium obtained from
lipopolysaccharide-induced peritoneal macrophages. How-
ever, whereas these mice were reported to continue to lose
weight, the weight loss in human recombinant TNF-treated
mice only occurs over the first 24h; thereafter the weight of
treated mice returns towards that of controls, as does the
food and water consumption. Thus the anorexic effects of
TNF are confined to the initial exposure, and thereafter the
animals become resistant to subsequent dosing. This prob-
ably explains the lack of weight loss in cancer patients
administered TNF in phase 1 studies (Blick et al., 1987).
However, progressive weight loss has been observed in mice
bearing CHO cells transfected with the human TNF/
cachectin gene (Oliff et al., 1987). This weight loss appeared
to be due, at least in part, to reduced food consumption.
The weight loss induced by TNF appears to be directly
related to the decrease in food and water consumption since
animals fed the same amount of food and water lost the
same amount of weight as the TNF treated group. In
addition the body composition of the pair-fed group did not
differ significantly from the TNF treated animals. No muscle
breakdown occurred either after semi-starvation or after
chronic administration of TNF at any of the concentrations
employed.
The initial weight loss produced by TNF is associated with
a marked and possibly life-threatening hypoglycaemia. While
administration of lipopolysaccharide has been shown to
induce hypoglycaemia, Satomia et al. (1985) reported no
hypoglycaemia in mice administered highly purified TNF.
However, Kettlehut et al. (1987) have recently demonstrated
large biphasic changes in blood glucose levels after TNF
induce hypoglycaemia, Satomi et al. (1985) reported no
decrease in blood glucose. Since the TNF-induced hypo-
glycaemia which we observed is directly proportional to both
the decrease in food and water intake and to the decrease in
body weight of mice and, since no hypoglycaemia is
observed after 5 daily injections of TNF when the mice are
regaining weight, this may be an important feature in the
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Table II Effect of recombinant TNF, pair-feeding and mitozolomide on the body composition of female NMRI mice*
Water content1 Fat content2 Muscle content3
(g) (g) (g)
Treatment Acute Chronic Acute Chronic Acute Chronic
Controls - no treatment 13.07 - 2.30 - 0.0695
+0.362 - +0.19 - +0.005 -
Controls - i.v. salines 13.11 12.56 2.20 1.79 0.065 0.0613
+0.24 +0.20 +0.11 +0.12 +0.0015 +0.002
Controls - i.p. arachis oil ± 10% DMSO 13.25 - 1.79 - 0.0685 -
+0.52 - +0.10 - +0.007 -
Control pair-fed 11.80a 11.54 1.62a 0.916 0.062 0.053
+0.24 +0.40 +0.13 +0.107 +0.003 +0.004
Mitozolomide 20mgkg1 11.70C - 1.84 - 0.062 -
+0.168 - +0.22 - +0.0005 -
TNF 7.5 x 10Ukg-1
I .99b 13.35b 1.54d 0.6Id 0.067 0.063
+0.09 +0.18 +0.23 +0.08 +0.023 +0.003
*Results are given as means+s.e.m. for 6 to 13 animals per group. Starting weight for animals in all groups 19.2±0.46g (n = 57);
Body water content in g; 2Body fat content in g; 3Left thigh and left gastrocnemius muscles in g; aP<0.01 from controls - no
treatment; bp<0.05 from controls - i.v. saline; CP<0.01 from controls - arachis oil; dp<0.01 from controls - i.v. saline.
metabolic perturbations induced by TNF. The observed
hypoglycaemia is probably due to a direct action of TNF,
and not merely due to a decrease in food and water
consumption since the decrease in blood glucose is much
more pronounced in TNF injected animals (7.5 x 107 Ukg-1)
than in pair-fed mice, even though the latter consumed the
same amount of food and water, or in mitozolomide-treated
mice despite a decrease in body weight with a decrease in
nutrient intake. This severe hypoglycaemia could possibly be
due to TNF stimulating glucose uptake and oxidation.
Semb et al. (1987) has recently shown that the suppression
of lipoprotein lipase activity by TNF is confined to adipose
tissue and that increased enzyme activity is observed in
several other tissues, most notably the liver and also in
plasma. Although fasting also leads to a decrease in lipopro-
tein lipase activity in epididymal adipose tissue the effect of
TNF on adipocyte gene expression differs from that in the
fasted state.. We have observed a marked hypertriglycer-
idemia and a decreased level of FFA in mice 60 to 90min
after the second of two injections of human TNF over a 24h
period. This hypertriglyceridemia probably arises from an
inhibition of adipocyte lipoprotein lipase, since the pool of
plasma triglyceride is comparatively small and a minor
impairment of the triglyceride removal mechanism would
probably increase the size of this plasma pool (Nilsson-Ehle,
1980). Although there was no correlation with the increase in
triglyceride levels and the weight loss of mice, the decrease in
plasma FFA observed was directly proportional to the
weight loss in TNF-treated mice. Lipoprotein lipase inhibi-
tion and hence increased plasma triglyceride levels is due to
a direct action of TNF and not merely due to a decrease in
nutrient intake as mitozolomide-treated and pair-fed mice
showed no changes in the level of circulating triglycerides.
The results suggest that the weight loss produced by TNF
appears to arise from an anorexic or toxic effect of this
agent, and that animals become refractory to subsequent
administration of this cytokine.
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